Global Lung Cancer Therapeutics Market 2012-2016

Table of Contents

01. Executive Summary
02. Introduction
03. Market Coverage
Market Overview
Key Products
04. Market Landscape
Market Size
Market Forecast
04.1 Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
US
Germany
Japan
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Hoffmann-La Roche Ltd.
Business Overview
Key Information
SWOT Analysis
15.2 Eli Lilly and Co.
Business Overview
Key Information
SWOT Analysis
15.3 Sanofi S.A.
Business Overview
Key Information
SWOT Analysis
15.4 Bristol-Myers Squibb Co.
Business Overview
Key Information
SWOT Analysis
15.5 AstraZeneca plc
Business Overview
Key Information
SWOT Analysis
15.6 Novartis AG
Business Overview
Key Information
SWOT Analysis
15.7 GlaxoSmithKline plc
Business Overview
Key Information
SWOT Analysis
16. Other Reports in this Series



List of Exhibits:

Exhibit 1: Global Lung Cancer Therapeutics Market 2012-2016 (US$ billion)
Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012
Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012
Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012
Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.
Exhibit 6: Business Segmentation of Eli Lilly and Co.
Exhibit 7: Business Segmentation of Sanofi S.A.
Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.
Exhibit 9: Business Segmentation of AstraZeneca plc
Exhibit 10: Business Segmentation of Novartis AG
Exhibit 11: Business Segmentation of GlaxoSmithKline plc